1. Scrip
  2. >>Therapy Areas

Dr Reddy's launches fentanyl transdermal patch in India

 
• By Anju Ghangurde

Dr Reddy's Laboratories has launched a fentanyl transdermal patch 25μg/hr and 50μg/hr (marketed as Finrid) in India. The product has been licensed from Sparsha Pharma, an Indian transdermal products firm, and is used in the management of severe to moderate pain. Finrid provides continuous systemic delivery of fentanyl, a potent opioid analgesic, for up to 72 hours.

Dr Reddy's Laboratories has launched a fentanyl transdermal patch 25μg/hr and 50μg/hr (marketed as Finrid) in India. The product has been licensed from Sparsha Pharma, an Indian transdermal products firm, and is used in the management of severe to moderate pain. Finrid provides continuous systemic delivery of fentanyl, a potent opioid analgesic, for up to 72 hours.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?